Asia Pacific RNAi Therapeutics Market Analysis and Opportunities by 2027
Historic Data: 2017-2018 | Base Year: 2019 | Forecast Period: 2020-2027Asia Pacific RNAi Therapeutics Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Molecule Type (Small Interfering RNAs (siRNA) and MicroRNA (miRNA)), Application (Genetic Disorders, Oncology, Neurodegenerative Disorders, Cardiovascular, Respiratory Disorders, Infectious Diseases, Renal Diseases, and Others), Route of Administration (Intradermal Injections, Pulmonary Delivery, Intravenous Injections, Intraperitoneal Injections, and Others), and End User (Diagnostic Laboratories, Research and Academic Laboratories, and Hospitals) and Geography
- Report Date : Oct 2020
- Report Code : TIPRE00015147
- Category : Life Sciences
- Status : Published
- Available Report Formats :
- No. of Pages : 133
The Asia Pacific RNAi therapeutics market is expected to reach US$ 218.64 million by 2027 from US$ 107.63 million in 2019. The market is estimated to grow at a CAGR of 9.3% from 2020 to 2027.
Growing investments in RNAi therapies and rising prevalence of infectious diseases & chronic conditions in Asia Pacific are the key factors driving the growth of RNAi therapeutics. However, high cost of RNAi therapies is the major factor hindering the market growth in Asia Pacific.
RNAi refers to the interference RNA which is responsible to control and manipulate protein translation in the cell. These RNAi are used to silence particular genes which are responsible for diseases. Currently, the awareness about RNAi is increasing extensively due to its ability to offer target specific mechanism, leading to superior treatment outcomes. The approach is widely utilized for drug development. Increasing number of investments in RNAi therapy development coupled with growing prevalence of infectious diseases and chronic conditions are anticipated to drive the Asia Pacific RNAi Therapeutics market during the forecast period.
Continuous R&D activities in RNAi therapeutics have revealed its benefits in tackling a range of chronic disorders, such as genetic conditions, renal disorders, neurodegenerative conditions, and oncology. The effectiveness of outcomes of RNAi therapies is generating investments in the development of new drugs. For instance, in June 2020, OliX Pharmaceuticals signed an agreement with LGC Biosearch technologies to accelerate production of asymmetric siRNA for the treatment of sub-retinal fibrosis and wet macular degeneration. Also, NantVentures made a private investment in public Australia based biotech Benitec Biopharma. Furthermore, Benitech and NantVentures, with the help of NantWorks, plan to begin an oncology-focused R&D collaboration with clinical development and preclinical evaluation that is to be led by Benitec. Moreover, in July 2018, Axovant Sciences signed a gene therapy licensing and development deal with Benitec Biopharma. As part of the deal, Axovant Sciences made an upfront payment of US$ 10 million to Benitec, which is also eligible for additional payments based on regulatory, development, and commercial sales milestones. Such investments help biotech and pharma companies not only launch new products but also increase number of approved products. The market players are gaining investments in the R&D of new drugs, therapies, and technologies. These increasing investments in RNAi therapeutics are driving the growth of the market.
Countries in Asia Pacific are severely affected by the COVID-19 outbreak. Several companies operating in this region are developing therapies for COVID-19. South Korea based OliX Pharmaceuticals, Inc., a leading developer of RNA interference (RNAi), announced that it would leverage previous preclinical research for developing siRNA therapeutics in treating respiratory illnesses to investigate a path forward for developing a COVID-19 therapy. Such continuous developments of RNAi therapies in Asia Pacific are likely to propel the market growth in this region.
Rest of Asia Pacific RNAi Therapeutics Market, Revenue, and Forecast to 2027 (US$ Million)
- This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.
Asia Pacific RNAi Therapeutics Market Segmentation
By Molecule Type
- Small Interfering RNAs (siRNA)
- MicroRNA (miRNA)
By Route of Administration
- Pulmonary Delivery
- Intravenous Injections
- Intradermal Injections
- Intraperitoneal Injections
- Others
By Application
- Oncology
- Cardiovascular
- Respiratory Disorders
- Renal Diseases
- Genetic Disorders
- Neurodegenerative Disorders
- Infectious Diseases
- Others
By End User
- Research and Academic Laboratories
- Hospitals
- Diagnostic Laboratories
By Country
- Japan
- China
- India
- South Korea
- Australia
Company Profiles
- Benitec Biopharma
- GlaxoSmithKline plc
- Olix Pharmaceuticals, Inc.
- Alnylam Pharmaceuticals, Inc.
- Arrowhead Pharmaceuticals, Inc.
Asia Pacific RNAi Therapeutics Report Scope
| Report Attribute | Details |
|---|---|
| Market size in 2019 | US$ 107.63 Million |
| Market Size by 2027 | US$ 218.64 Million |
| Global CAGR (2020 - 2027) | 9.3% |
| Historical Data | 2017-2018 |
| Forecast period | 2020-2027 |
| Segments Covered |
By Molecule Type
|
| Regions and Countries Covered | Asia-Pacific
|
| Market leaders and key company profiles |
Market Research & Consulting
- Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
- PEST and SWOT Analysis
- Market Size Value / Volume - Global, Regional, Country
- Industry and Competitive Landscape
- Excel Dataset
Testimonials
I wish to appreciate your support and the professionalism you displayed in the course of attending to my request for information regarding to infectious disease IVD market in Nigeria. I appreciate your patience, your guidance, and the fact that you were willing to offer a discount, which eventually made it possible for us to close a deal. I look forward to engaging The Insight Partners in the future, all thanks to the impression you have created in me as a result of this first encounter.
DR CHIJIOKE ONYIA, MANAGING DIRECTOR, PineCrest Healthcare Ltd.
The Insight Partners delivered insightful, well-structured market research with strong domain expertise. Their team was professional and responsive throughout. The user-friendly website made accessing industry reports seamless. We highly recommend them for reliable, high-quality research services
Yukihiko Adachi CEO, Deep Blue, LLC.Reason to Buy
- Informed Decision-Making
- Understanding Market Dynamics
- Competitive Analysis
- Customer Insights
- Market Forecasts
- Risk Mitigation
- Strategic Planning
- Investment Justification
- Identifying Emerging Markets
- Enhancing Marketing Strategies
- Boosting Operational Efficiency
- Tracking Industry Innovations
- Aligning with Regulatory Trends
Yes! We provide a free sample of the report, which includes Report Scope (Table of Contents), report structure, and selected insights to help you assess the value of the full report. Please click on the "Download Sample" button or contact us to receive your copy.
Absolutely — analyst assistance is part of the package. You can connect with our analyst post-purchase to clarify report insights, methodology or discuss how the findings apply to your business needs.
Once your order is successfully placed, you will receive a confirmation email along with your invoice.
• For published reports: You’ll receive access to the report within 4–6 working hours via a secured email sent to your email.
• For upcoming reports: Your order will be recorded as a pre-booking. Our team will share the estimated release date and keep you informed of any updates. As soon as the report is published, it will be delivered to your registered email.
We offer customization options to align the report with your specific objectives. Whether you need deeper insights into a particular region, industry segment, competitor analysis, or data cut, our research team can tailor the report accordingly. Please share your requirements with us, and we’ll be happy to provide a customized proposal or scope.
The report is available in either PDF format or as an Excel dataset, depending on the license you choose.
The PDF version provides the full analysis and visuals in a ready-to-read format. The Excel dataset includes all underlying data tables for easy manipulation and further analysis.
Please review the license options at checkout or contact us to confirm which formats are included with your purchase.
Our payment process is fully secure and PCI-DSS compliant.
We use trusted and encrypted payment gateways to ensure that all transactions are protected with industry-standard SSL encryption. Your payment details are never stored on our servers and are handled securely by certified third-party processors.
You can make your purchase with confidence, knowing your personal and financial information is safe with us.
Yes, we do offer special pricing for bulk purchases.
If you're interested in purchasing multiple reports, we’re happy to provide a customized bundle offer or volume-based discount tailored to your needs. Please contact our sales team with the list of reports you’re considering, and we’ll share a personalized quote.
Yes, absolutely.
Our team is available to help you make an informed decision. Whether you have questions about the report’s scope, methodology, customization options, or which license suits you best, we’re here to assist. Please reach out to us at sales@theinsightpartners.com, and one of our representatives will get in touch promptly.
Yes, a billing invoice will be automatically generated and sent to your registered email upon successful completion of your purchase.
If you need the invoice in a specific format or require additional details (such as company name, GST, or VAT information), feel free to contact us, and we’ll be happy to assist.
Yes, certainly.
If you encounter any difficulties accessing or receiving your report, our support team is ready to assist you. Simply reach out to us via email or live chat with your order information, and we’ll ensure the issue is resolved quickly so you can access your report without interruption.
- Benitec Biopharma
- Olix Pharmaceuticals, Inc.
- GlaxoSmithKline plc
- Alnylam Pharmaceuticals, Inc.
- Arrowhead Pharmaceuticals, Inc
Get Free Sample For